BIOLIFE4D is committed to perfecting the technology to make viable organ replacement a safe, accessible and affordable reality. With BIOLIFE4D, a patient-specific, fully functioning heart will be created through 3D bioprinting and the patient’s own cells, eliminating the challenges of organ rejection and long donor waiting lists that plague existing organ transplant methods.
BIOPRINTING
What if we could print a human heart? Science has found a way. This is not science fiction. This is science fact. This is BIOLIFE4D.
BIOLIFE4D PROCESS
It starts with a patient’s own cells and ends with a bioprinted heart that’s both a precise fit and perfect genetic match.
SIGNIFICANT MILESTONES
BIOLIFE4D in the News!
Chicago company 3D-bioprints mini human heart
By Anicka Slachta | Sept 10, 2019 According to a statement from BIOLIFE4D, the mini-heart was made possible through a combo of a proprietary bioink and a bioprinting algorithm optimized for whole-heart printing. When the bioink—a blend of different extracellular matrix compounds that closely mimic the properties of a mammalian heart—is combined with patient-derived cardiomyocytes,…
Latest Press Releases
BIOLIFE4D Becomes First U.S. Company to Successfully Demonstrate Ability to 3D Bioprint a Mini Human Heart
Pioneering biotech company reaches significant milestone, using proprietary bioink to successfully 3D bioprint a mini-heart with full structure of a whole heart, including chambers and ventricles CHICAGO – September 9, 2019 – BIOLIFE4D, a biotech pioneer leveraging advances in tissue engineering to 3D print human organs viable for transplant, today announced it has successfully demonstrated its…
Recent Blogs
Kate Lewis chosen as BIOLIFE4D’s First President!
Everyone at BIOLIFE4D is proud to announce our newest addition to our executive team, Kate Lewis. A pharmaceutical veteran and our company’s first female executive, Kate will proudly lead commercialization efforts of BIOLIFE4D’s live-saving 3D bioprinting technologies. Kate brings more than 25 years of experience and relationships from within the pharmaceutical, transplantation, and regulatory industries….
